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Abstract 
Background: Although originally marketed as safe alternatives to the habit-forming 
benzodiazepines, growing numbers of zaleplon, zolpidem, and zopiclone (‘Z-drugs’) 
clinical concerns relating to their potential of abuse, dependence and withdrawal have 
been reported overtime.  We aimed here at assessing these issues analysing datasets 
of Adverse Drug Reactions (ADR) provided by the European Medicines Agency (EMA) 
through the EudraVigilance (EV) system.  
Methods: Analysing the ADR databases of each Z-drug, descriptive analyses have been 
performed on cases, and Proportional Reporting Ratios (PRRs) computed. 
Results: An overall number of 33,240 (e.g. 23,420 zolpidem; 9,283 zopiclone; and 537 
zaleplon) misuse/abuse/dependence/withdrawal-related ADRs, corresponding to some 
6,246 unique patients given Z-drugs, were here identified. Cases were studied and 
described, including demographic characteristics and clinical data, such as concomitant 
drugs, doses, routes of administration, and outcomes of the reactions, being fatalities 
recorded. Considering PRR values, and in comparison with zopiclone, zolpidem was 
more frequently involved in both misuse/abuse and withdrawal issues. Zolpidem and 
zopiclone presented with the same dependence risk, but zopiclone was the most 
involved in overdose ADRs. If compared with zaleplon, zopiclone presented higher 
D
ow
nloaded from
 https://academ
ic.oup.com
/ijnp/advance-article-abstract/doi/10.1093/ijnp/pyz007/5306970 by :: user on 07 February 2019
Ac
ce
pte
d M
an
us
cri
pt
 
4 
 
dependence and overdose-related issues, but slightly lower misuse/abuse and 
withdrawal PRR values.  
Conclusion: Current data may only represent a gross underestimate of the Z-drugs’ 
misusing issues’ real prevalence. Caution should be exercised when prescribing those 
molecules, especially for patients with psychiatric illnesses and/or history of drug 
abuse. We recommend the need to invest in proactive pharmacovigilance activities to 
better and promptly detect, understand and prevent any possible misusing potential of 
prescribed medications. 
Keywords: adverse drug reactions; Z-drugs; zolpidem; zaleplon; zopiclone; EMA. 
 
Significance Statement 
Although originally marketed as safe alternatives to the habit-forming benzodiazepines, 
growing concerns about zaleplon, zolpidem, and zopiclone (‘Z-drugs’) abuse, 
dependence and withdrawal issues have been reported overthe the last decade. . The 
analysis of Z-drugs’ related misuse/abuse/dependence/withdrawal cases collected by the 
European Medicines Agency (EMA) EudraVigilance (EV) database here provided 
provides firm, and large scale, evidence that Z-drugs may be abused for recreational 
purposes. Physicians should prescribe Z-drugs with caution, especially to vulnerable 
clients  
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Introduction 
Although sharing with benzodiazepines a similar mechanism of action, the non-
benzodiazepine hypnotics zaleplon, zolpidem, and zopiclone (‘Z-drugs’) appeared on 
the market as safe substitutes for benzodiazepines, purportedly having both a reduced 
abuse potential and propensity to tolerance and withdrawal due to improved 
pharmacokinetics (Gunja N, 2013). Despite such expectations, large levels of cases of 
misuse, abuse, dependence and death involving Z-drugs have been reported over the last 
decade or so (Atkin et al., 2018).  
 
Clinical pharmacological issues 
Z-drugs are GABA-A receptor modulators chemically unrelated to benzodiazepines 
approved for the short-term management of insomnia disorders (NICE, 2004) due to 
their hypnotic effects by reducing sleep latency and improving sleep quality (Nutt and 
Stahl, 2010). Like benzodiazepines, Z-drugs are agonists of the GABA receptor 
complex and therefore enhancing GABA-mediated neuronal inhibition. However, their 
binding selectivity and pharmacokinetic profiles have been reported to minimise the 
possibility of side-effects similar to those produced by benzodiazepines, e.g. next day 
sedation, dependence and withdrawal (NICE, 2004). 
Among Z-drugs, zopiclone was the first compound developed, binding with high 
affinity and functional potency the benzodiazepine receptor complex. With an 
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absorption time of about 2 hours and an elimination half-life of 4-5 hours, its clinical 
use is in the 3.75–7.5 mg dosage range (EMC. Zopiclone, 2017). Zolpidem is an 
imidazopyridine with an oral bioavailability of 70% and an elimination half-life of 2.5 
hours (NICE, 2004; Nutt and Stahl, 2010). It is normally indicated at 10mg dosages 
(Victorri-Vigneau et al., 2007). Zaleplon is a rapidly absorbed pyrazolopyrimidine, with 
an elimination half-life of 1 hour (NICE, 2004). Zaleplon use, at 5–20 mg dosage, is 
currently indicated only for use in patients with initial insomnia, and an extended-
release formulation is in development (Ebert et al., 2006). Z-drugs treatment should 
usually vary from a few days to 2 weeks with a maximum of 4 weeks, including 
tapering-off where appropriate. 
 
Misuse, abuse, dependence and withdrawal issues  
Despite the reported lack of tolerance and dependence (Lader, 1992; Voderholzer et al., 
2001; Zammit G, 2009), the occurrence of both rebound insomnia (Lader, 1992; Ebert 
et al., 2006) and withdrawal symptoms after a therapeutic dosage abrupt discontinuation 
of Z-drugs has been described, and especially so in alcohol-dependent  and drug 
abusing patients (Ayorinde and Sampson, 1998; Hajak G, 1999; Hajak et al., 2003; 
Johansson et al., 2003; Ebert et al., 2006; Zammit G, 2009; Morinan and Keaney, 2010). 
Furthermore, a range of case series and post-marketing surveillance studies have given 
rise to growing levels of clinical concerns among clinicians (Victorri-Vigneau et al., 
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2014), suggesting that the prevalence of Z-drugs’ misusing issues could have been 
underestimated compared with benzodiazepines (Zammit, 2009). Z-drugs’ withdrawal 
symptoms, typically associated with the abrupt cessation of long-term, high dosage 
intake may include: insomnia, anxiety, euphoria irritability, tremor, inner restlessness, 
speech difficulties, abdominal pain, hypertension, tonic-clonic seizures, and 
confusion/disorientation/delirium (Aranko et al., 1991; Wong et al., 2005; Flynn and 
Cox, 2006). The use of either idiosyncratic routes of administration (e.g. injecting) or 
the intake of high dosages, may well increase the risk of Z-drugs’ abuse (Victorri-
Vigneau et al., 2007). Drug misusers may be attracted by Z-drugs because they are not 
typically monitored during drug treatment programmes (Sikdar and Ruben, 1996; 
Rooney and O'Connor, 1998; Gunja, 2013; Ott et al., 2017; Schifano et al., 2018).   
 
Z-drugs current regulation; near misses; and fatalities 
According to the World Health Organization (WHO) the occurrence of zolpidem abuse 
and dependence would be similar to that of benzodiazepines and, different from 
zopiclone and zaleplon, in 2001 this molecule was placed in the same schedule of 
benzodiazepines (UNODC, 2001). Conversely, in 2013 the UK’s Advisory Council on 
the Misuse of Drugs (ACMD) concluded that zaleplon and zopiclone should be 
controlled in the same manner as zolpidem. Overall, zaleplon tends to be reported as the 
least misused, while zopiclone and zolpidem are both identified as the most misused 
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(ACMD, 2013).  
 
To assess the Z-drugs’ misuse/abuse/dependence and withdrawal-related issues, our 
study aimed at analysing the related EMA EudraVigilance (EV) databases, collecting 
the voluntary reports of suspected ADRs for all medicinal products authorized in the 
European Economic Area/EEA. 
 
Methods 
The European pharmacovigilance system and its functions of detection, assessment, 
understanding, and prevention of adverse drug reactions (ADRs) or any other drug-
related problem have been improved in parallel with the 2012 pharmacovigilance 
legislation (EMA EV 2016; Sessa et al., 2018). The European Medicines Agency 
(EMA) is responsible for the safety monitoring of medicines operating through 
EudraVigilance (EV), a system managing and analysing information on suspected 
ADRs to medicines which have been authorised in the European Economic Area (EEA) 
(EMA EV, 2016), although reports are received non-EEA countries as well (for a better 
understanding of the EMA organization of data collection, please refer to the paper 
supplementary material).  
In order to assess the Z-drugs’ misusing issues, a formal request was sent to EMA for all 
abuse/misuse/dependence/withdrawal Z-drug-related data. The Individual Case Safety 
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Reports (ICSR) were identified considering the Preferred Terms (PTs) mentioned. The 
request included the following PTs: ‘drug abuse’, ‘intentional product misuse’, ‘drug 
dependence’ and ‘withdrawal syndrome’ or all the PTs terms included in the broad 
Standardised MedDRA Queries (SMQ) ‘Drug abuse, dependence and withdrawal’ 
(MedDRA, 2010). The level 2A EV frequency table and line listing of the requested 
ADRs were here retrieved. Level 2A access meant that cases were provided with 
general information (e.g. sender, type of report, reporter qualification), some 
anonymised patient information, reaction (event) information with its outcome, and 
drug-related information (e.g. start date, duration, dose, pharmacological form, route of 
administration) (see also EMA, 2018). In the EV database each individual patient had a 
code (EV local number) for unequivocal identification. ADRs’ numbers differed from 
those referring to single patients, since different reporters/senders could have 
independently flagged the same ADR to EMA. Conversely, several ADRs (involving 
various organ classes, hence identified with specific PTs) relating to the searched ADR 
(e.g. abuse/misuse/dependence and withdrawal) could have been reported as well for the 
same patient (HMA EMA, 2017). The zolpidem, zopiclone, and zaleplon data analysis 
referred to a range of parameters, including: socio-demographic characteristics (age and 
sex); source/reporter country (EEA or non-EEA) and reporter qualification (i.e. 
pharmacist, physician); ADR outcome (fatal, recovered, resolved); drug dosages; and 
possible concomitant drug(s). The analysis included cases of abuse/misuse/dependence 
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and withdrawal ADRs, focusing on fatalities as well. Suicides were here reported as 
‘suicide attempt’, ‘suicidal behaviour’ and ‘intentional self-injury’; conversely, ‘suicidal 
ideation’, and ‘overdose’ (including intentional) were not included (MedDRA, 2010). 
The ADRs considered here were, per se, voluntary and unsolicited communications 
reported by both Regulatory Authorities of the EU Member States where the reaction 
occurred, and/or by the Marketing Authorisation Holders for those ADRs occurring 
outside the EEA. Within the SMQs ‘drug abuse, dependence and withdrawal’ section 
the following adverse reactions were identified: dependence, drug abuser, drug 
diversion, drug use disorder, drug withdrawal convulsions, drug withdrawal  headache, 
drug withdrawal syndrome, intentional overdose, intentional product misuse, intentional 
product use issue, overdose, prescription drug use without prescription, product use in 
unapproved indication, product use issue, substance use disorder, substance abuser, and 
withdrawal syndrome. ‘Misuse’ was here meant to be the ‘intentional use for a 
therapeutic purpose by a patient or consumer of a product, over-the-counter or 
prescription, other than as prescribed or not in accordance with the authorised product 
information’. Conversely, ‘abuse’ was defined here as the ‘intentional, non-therapeutic 
use by a patient or consumer of a product, over-the-counter or prescription, for a 
perceived reward or desired non-therapeutic effect including, but not limited to, getting 
high (euphoria)’. The term ‘addiction’, typically replaced by ‘dependence’, is the 
‘overwhelming desire by a patient or consumer to take a drug for non-therapeutic 
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purposes together with inability to control or stop its use despite harmful consequences’. 
Finally, ‘withdrawal’ referred here to: ‘a substance-specific syndrome which follows 
cessation or reduction in the intake of a psychoactive substance previously regularly 
used’ (MedDRA, 2010). Those ADRs which were listed as ‘suspect drug’, meaning that 
the reporter suspected this drug, and not the concomitant medicine(s), to have caused 
the index ADR (EMA EV, 2016) were here included. 
The Proportional Reporting Ratio (PRR) approach, defined as: ‘the ratio between the 
frequency with which a specific adverse event is reported for the drug of interest 
(relative to all adverse events reported for the drug) and the frequency with which the 
same adverse event is reported for the drug(s) in the comparison group (relative to all 
adverse events for drugs in the comparison group)’, was here considered (EMA EV-
Ewg, 2006). A PRR greater than 1 suggests that the adverse event is more commonly 
reported for individuals taking the drug of interest relative to the comparison drug(s), 
while if the PRR value is less than 1, there is a disproportion of reporting in the sense 
that the specific event is less frequently reported in association with the suspect drug 
than with the others. The PRR confidence intervals were here computed as well, 
indicating with PRR- and PRR+ respectively the lower and upper bounds of the 95% 
confidence interval (EMA EV-Ewg, 2006; for a better understanding of the PRR 
calculation, please refer to the paper supplementary material).  
Ethics 
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Because of EMA protection of privacy and integrity of individuals, data relating to 
patients affected were fully and completely de-identified/anonymised; therefore, it 
was not possible at all to derive from such data the names of the individuals affected 
by the ADR, not even their country or town. Hence, per definition, the need to obtain 
their informed consent was here not applicable. Moreover,  certain data elements (e.g. 
names/identifiers of individuals involved; country-specific information, nationally 
authorized products etc) were not disclosed (EMA, 2016).  
The study has been ethically approved by the University of Hertfordshire Ethics' 
Committee, with reference number LMS/PGR/UH/03234 (March 5th, 2018). 
 
Results 
Zaleplon ADRs 
Overall, the number of the EMA 2003-2017 zaleplon ADRs collected by was 4,270 
(Table 1). Out of the total number of ADRs, those relating to misuse-abuse-dependence-
withdrawal issues and judged by the reporter as ‘suspect' were 537 (12.58%), with 
‘intentional overdose’ being the most represented (51.9%). Most ADRs were reported 
by physicians from non-EEA countries (53.2%), whilst pharmaceutical companies were 
the most typical (58.6%) reporting agencies. Typically, these ADRs involved adult (18-
64 years old) females. A lone Z-drug ingestion was reported in 33/112 (29.4%) of 
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zaleplon, whilst a concomitant use of prescribing drugs mostly involved antidepressants 
(19.8%), benzodiazepines (17.8%), and ethanol/other Z-drugs (13.9%) has been 
described. A nasal atypical intake modality was reported in 7 zaleplon cases. No 
information of dosage was here provided. 
Finally, a range of suicide-related (‘suicide attempt’ and ‘suicidal ideation’) ADRs were 
reported (respectively 13.6% and 5.21%).   
 
Zolpidem ADRs 
Out of the total number of zolpidem ADRs (206,315), those relating to misuse-abuse-
dependence-withdrawal issues and judged by the reporter as ‘suspect' were 23,420 
(11.35%) (Table 1). Most ADRs were reported by physicians from non-EEA countries 
(49.7%), pharmaceutical companies having been the most typical (41.3%) reporting 
agencies. ‘Drug use disorder’ (40.0%), ‘overdose’ (23.7%), and ‘intentional overdose’ 
(16.7%) were the most represented ADRs. Typically, these ADRs involved adult (18-64 
years old) females. A lone Z-drug ingestion was reported in 1,856/4,374 (42.4%) 
zolpidem cases, whilst a concomitant use of prescribing drugs was reported, mostly 
involving antidepressants (26.6%); benzodiazepines (19.0%); and opiates/opioids 
(14.2%). Moreover, a range of recreational drugs were identified, specifically: alcohol 
(174 cases); cocaine (30 cases); amphetamines (21 cases); and cannabis (13 cases). 
Atypical intravenous (22 cases); nasal (5 cases); and sublingual (1 case) intake 
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modalities were here reported for zolpidem. Dosages were higher than 20mg in 7,371 
ADRs; in 6,234 of these cases, the dosage was above 100mg; and in 20 ADRs (7 cases) 
it was in excess of 2,000mg. Finally, a range of suicidal behaviour-related ADRs were 
reported for zolpidem, including: ‘intentional self-injury’ (102/23,420: 0.5%); ‘suicidal 
behaviour’ (44/23,420: 0.2%); and ‘suicide attempt’ (3,101/23,420: 13.2%). The rates of 
ADRs with a fatal outcome were higher for zolpidem (20.3%) in comparison with both 
zopiclone (9.33%) and zaleplon (1.1%). 
 
Zopiclone ADRs 
As for zaleplon and zolpidem, most zopiclone-related ADRs were reported by 
physicians from non-EEA countries (45.8%), with pharmaceutical companies having 
been the most typical (51.4%) reporting agencies. Out of the total number of ADRs 
(65,140), those relating to misuse-abuse-dependence-withdrawal issues and judged by 
the reporter as ‘suspect' were 9,283 (14.25%) (Table 1), with the most represented 
ADRs including: ‘intentional overdose’ (29.9%); ‘overdose’ (23.1%); and ‘drug use 
disorder’ (23.1%). Typically, these ADRs involved adult (18-64 years old) females. A 
lone zopiclone ingestion was reported in 416/1,760 (23.6%) cases; as for zaleplon and 
zolpidem, a concomitant use of prescribing drugs was reported, mostly involving: 
benzodiazepines in 891/4,374 (20.4%) cases; antidepressants in 658/4,374 (15.0%) 
cases; antipsychotics in 475/4,374 (10.9%) cases; and opiates/opioids in 131/4,374 
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cases (2.99%). Moreover, a range of recreational drugs were identified (e.g. cannabis in 
12 cases; cocaine in 6 cases; methamphetamines in 1 case); and intravenous and 
subcutaneous intake modalities were reported as well. Finally, as for zolpidem, a range 
of suicidal behaviour-related ADRs were reported, including: ‘intentional self-injury’ 
(111/9,283:1.2%); ‘suicidal behaviour’ (43/9,283: 0.5%); and ‘suicide attempt’ 
(2,526/9,283: 27.2%). When dosages were reported, levels in excess of 15mg were 
described in 577 (360 individuals) of zopiclone cases, including 205 ADRs (120 cases) 
where the dosage ingested was in the 450-2,250mg range. 
 
Analysis of the PRR values  
Considering the PRR values (Tables 2 and 3), in comparison with zopiclone, zolpidem 
was more involved in both misuse/abuse and withdrawal issues, whilst zopiclone was 
more involved in overdose ADRs. Conversely, zolpidem and zopiclone presented with 
the same dependence risk. If compared with zaleplon, zopiclone and zolpidem presented 
higher dependence and withdrawal, but slightly lower misuse/abuse and withdrawal, 
PRR values. Lower and upper bounds of the PRR confidence interval are reported in 
Table 3.  
 
Discussion 
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To the best of our understanding, this paper is the first to provide uniquely systematic 
data in terms of identification and analysis of zolpidem; zopiclone; and zaleplon 
misuse/abuse/dependence and withdrawal issues. Present data were extracted from a 
high-quality, large-scale, pharmacovigilance database such as the EMA’s EV. Together 
with the World Health Organization’s Drug Monitoring Program, the EV database is 
considered a worldwide reference standard (Schifano and Chiappini, 2018). Most 
literature papers, so far, were based on small case series/single case studies (Aranko et 
al., 1991; Sikdar and Ruben, 1996; Rooney and O'Connor, 1998; Wong et al., 2005; 
Flynn and Cox, 2006; Chiaro et al., 2018). Conversely, current findings referred to 
overall much larger (e.g. 33,240 ADRs; corresponding to some 6,246 unique cases) 
numbers of patients presenting with Z-drugs’ misusing issues. Indeed, current data may 
only represent a gross under estimate of the Z-drugs’ misusing issues’ real prevalence. 
In fact, reports were here submitted spontaneously, and levels of misperception that 
these drugs are safe, which could prevent professionals from reporting, may still be 
identified (Medsafe, 1998). The analyses of the EV databases confirmed the diversion 
potential and the possibility of abuse/misuse/dependence and withdrawal issues related 
to all Z-drugs (zaleplon, zopiclone, and zolpidem), albeit some differences have 
emerged within this group. In comparison with zaleplon the misuse/abuse issues seemed 
here to be lower for zopiclone and zolpidem. , Conversely, if compared with zopiclone, 
zolpidem emerged as being more frequently related to misuse/abuse; and withdrawal 
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reports; if compared  with zaleplon, zolpidem was more frequently related to 
dependence; and overdose reports.. Among Z-drugs, zolpidem was the most frequently 
reported in the EV dataset, being associated with intravenous administration; very high 
dosage consumption; and concomitant use of recreational drugs. These data are 
consistent with previous suggestions (Griffiths and Johnson, 2005; Rousselet et al., 
2017) and recent reports based on both zolpidem-related falsified prescriptions’ rates in 
France (Jouanjus et al., 2018) and clinical dependence issues’ data from an Indian 
tertiary care centre (Shukla et al., 2016). Overall, zaleplon ADRs were: numerically 
lower than zopiclone- and zolpidem-related ADRs; and less frequently associated with 
both idiosyncratic/atypical ways of administration and concomitant recreational drug 
intake. Hence, one could tentatively identify in zaleplon the relatively (Desousa, 2009; 
Paparrigopulos et al., 2009) ‘most safe’ Z-drug, A full comparison among Z-drugs’ 
should however consider as well the precise worldwide prescription figures, which 
could serve as a proper denominator. Indeed, within the Z-drug group, one could argue 
that zaleplon may present with the lowest availability levels due to its higher purchase 
costs (NICE, 2004). Regarding zopiclone use, Jaffe et al (2004) assessed its use among 
297 drug addicts who had been consecutively admitted to addiction treatment centres in 
the United Kingdom (UK). It emerged that more than half had used zopiclone, which 
ranked fourth after diazepam, temazepam and nitrazepam. About 80% of zopiclone 
users had obtained the drug through a prescription, but 42% reported having purchased 
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it on the streets (Jaffe et al., 2004). Analysing the misuse patterns of benzodiazepines 
and Z-drugs’ users, Kapil et al. reported that 29.6% had ever misused them, with 40.5% 
of individuals misusing at least two of these medications. Diazepam (53.4%) and 
zopiclone (24.1%) were the most frequently reported medications, with decreasing 
numbers of individuals misusing lorazepam (22.4%), alprazolam (17.2%), zaleplon 
(11.2%), nitrazepam (10.3%), phenazepam (7.8%) and zolpidem (5.2%). Moreover, 
iUsing data from a Health Insurance reimbursement database, which collects 
information of 77% of the French population, Ponté et al. (2018) assessed the extent and 
risk of abuse of opioid analgesics related to benzodiazepines and hypnotics; they 
considered both the molecules’ Doctor Shopping Quantity/DSQ (intended to assess the 
extent of abuse) and the Doctor Shopping Index/DSI (intended to identify a signal of 
abuse). Interestingly, they found that the DSQ of anxiolytics and hypnotics (influenced 
by their large availability levels) was 10 times higher than that of opioids. Conversely, 
the DSI of opioids (2.79%) was higher than the one of both hypnotics (2.06%) and 
anxiolytics (1.81%). Among benzodiazepines, flunitrazepam and zolpidem presented 
with the highest DSI values (13.2% and 2.2% respectively) (Ponté et al., 2018). Overall, 
higher levels of physical and compulsive signs of dependence with zolpidem, rather 
than with zopiclone (Griffiths and Johnson, 2005; Rousselet et al., 2017; Ponté et al., 
2018), have been described .  
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Current Z-drugs’ data are consistent with the new trends in prescribing drugs’ misuse 
(Throckmorton et al., 2018), which is at times occurring within the context of the rising 
levels of Novel Psychoactive Substances (NPS) misuse (Schifano et al., 2018). It is 
however a reason of concern that a range of further, prescribing and recreational, 
psychotropics were here identified in combination with Z-drugs, including: 
antidepressants, benzodiazepines, antipsychotics, other Z-drugs, opiates/opioids, 
alcohol, cannabis, cocaine, methamphetamine, and ketamine. Present data may support 
previous hypotheses, e.g. that there may two sub-sets of individuals misusing with Z-
drugs; the first group may include patients with psychiatric comorbidities (Zammit G, 
2009; Lin et al., 2017), who were originally started with these molecules for insomnia 
but who developed tolerance and withdrawal phenomena, requiring increasing dosages 
overtime (Griffiths and Johnson, 2005); and the second population may include young 
people, who are ingesting large Z-drug dosages in combination with other recreational 
compounds and through idiosyncratic intake modalities (Sikdar and Ruben, 1996; 
Ayorinde and Sampson, 1998; Rooney and O’Connor, 1998; Hajak G, 1999; Johansson 
et al., 2003), which can increase the drug bioavailability levels (Victorri-Vigneau et al., 
2007) and hence facilitate achieving better euphoria.  
Fatalities were here reported for all Z-drugs, although this typically occurred mostly 
with zolpidem, and zopiclone, both typically ingested in a poly-drug misuse scenario, 
thus confirming previous reports(Garnier et al., 1994; Casula et al., 2013; Gunja , 2013). 
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The comparatively low levels of zaleplon toxicity/fatalities here identified could 
however be associated with the molecule ultra-short half-life and rapid ante-mortem 
metabolism, which can affect its detection (Gunja, 2013). Mortality from Z-drugs may 
be similar to that of benzodiazepines (Garnier et al., 1994; ) Reith et al., 2003). A UK 
study on zopiclone-related deaths (Buckley and McManus, 2004) found that the 
zopiclone fatal toxicity index was similar to that of zolpidem but lower if compared 
with flurazepam, flunitrazepam, temazepam, triazolam, and nitrazepam. It is of interest 
to note that a number of suicidal behaviour-related ADRs (e.g. suicide attempts; suicidal 
ideation) were here identified, and especially so for both zolpidem and zopiclone. This 
confirms previous findings, suggesting increasing levels of suicidal ideation, suicide 
attempts, and suicide risk in patients administered with Z-drugs (Brower et al., 2011; 
MCCall et al., 2017). 
 
Limitations 
The number of any given compound-related ADRs may not reflect the full extent of the 
molecule’s potential of misuse. In fact, levels of reporting, which is voluntary in nature, 
are depending on the index molecule clinicians’ awareness of safety concerns; its 
market availability levels; and extent of use. Furthermore, a Z-drugs’ illicit market 
exists (Kapil et al., 2014), further complicating the computation of a reliable, Z-drugs’ 
availability levels, denominator. The ADRs’ reports presented here with missing data, 
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which often included both the dosages ingested and the background diagnosis. Based on 
the current reporting rules in the EEA, report duplications were here possible as well, 
i.e. the same ADR could be reported by different healthcare professionals. To mitigate 
this issue, however, the number of individual cases was here unequivocally iden ified 
through a code number. Finally, suspected ADRs do not conclusively prove causality 
between a specific drug and a given ADR; the ADR may be a symptom of another 
illness, it could be associated with another medical product taken by the patient at the 
same time or caused by their interaction. 
 
Conclusions 
In being perceived as more effective and tolerable hypnotics, the levels of Z-drugs’ 
availability has risen overtime, in parallel with a fall in benzodiazepine prescriptions  
(Siriwardena et al., 2006; ACMD, 2013). However, both previous number of anecdotal 
reports and current data may well suggest that the misuse/abuse/dependence and 
withdrawal issues may be associated with the use of all Z-drugs, although zaleplon may 
present with comparatively smaller levels of risk. Present data may further support the 
need of encouraging careful prescribing, in line with the UK government's initiative to 
review the evidence for dependence on, and withdrawal from, prescribed medicines 
(Pollman et al., 2015; Kuntz et al., 2017; Gov.uk, 2018). Special caution is here 
suggested in prescribing Z-drugs to vulnerable clients, e.g. inmates; those with 
D
ow
nloaded from
 https://academ
ic.oup.com
/ijnp/advance-article-abstract/doi/10.1093/ijnp/pyz007/5306970 by :: user on 07 February 2019
Ac
ce
pte
d M
an
us
cri
pt
 
23 
 
psychiatric comorbidities; and recreational drug misusers. To manage clinical Z-drugs’ 
dependence cases, the use of benzodiazepines (e.g. diazepam or clonazepam), 
gabapentinoids, trazodone, and quetiapine has been suggested (Mariani and Levin, 
2007; Pottie et al., 2018).  
Voluntary reporting systems should be improved, with new tools/approaches to be 
hopefully made available. To assess the abuse potential of centrally active drugs, a 
range of both pre-marketing evaluation and proactive post-marketing surveillance 
activities should be strongly encouraged. A proactive pharmacovigilance may help in 
monitoring and anticipate changes in drug abuse, using elements of clinical, 
epidemiological, basic science, and social science expertise in order to increase 
clinicians’ awareness of drug safety issues (Throckmorton et al., 2018). 
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Table 1: Number of EMA database Z-drugs’ (zaleplon, zopiclone, and zolpidem) misuse-/abuse-/dependence- 
and withdrawal-related ADRs (2003-2017). 
 ZALEPLON ZOPICLONE ZOLPIDEM 
Total no. ADRs 4,270 65,140 206,315 
Suspect 
abuse/misuse/depende
nce/withdrawal- 
related ADRs 
537 (12.58%)  
(IC 95%: 11.60-13.61%) 
9,283 (14.25%)  
(IC 95%: 13.98-14.52%) 
23,420 (11.35%)  
(IC 95%: 11.21-11.49%) 
No. of unique patients 112 1,760 4,374 
Gender most typically 
represented 
F (F/M ratio: 3.9) F (F/M ratio: 1.09) F (F/M ratio: 1.6) 
Age range (years) 
most typically 
represented 
18-64 (39%) 18-64 (68%) 18-64 (65.7%) 
ADRs most typically 
represented 
Intentional overdose (51.9%), 
overdose (14.1%), drug use disorder 
(11.4%) 
Intentional overdose (29.9%), overdose 
(23.1%), drug use disorder (23.1%) 
Drug use disorder (40.0%), overdose 
(23.7%), intentional overdose 
(16.7%) 
Concomitant drugs 
most typically 
represented 
Antidepressants in 20/101 (19.8%) 
cases, benzodiazepines in 18/101 
(17.8%) cases, ethanol/other Z drugs 
in 14/101 (13.9%) cases 
Benzodiazepines in 891/4,374 (20.4%) 
cases, antidepressants in 658/4,374 
(15.0%) cases, antipsychotics in 
475/4,374 (10.9%) cases 
Antidepressants in 468/1,760 (26.6%) 
cases, benzodiazepines in 334/1,760 
(19.0%) cases, opiates/opioids in 
250/1,760 (14.2%) cases 
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Table 2: Z-drugs (zaleplon, zolpidem and zopiclone) misuse-/abuse-
/dependence/withdrawal- and overdose-related ADRs; PRR computation. 
Zaleplon ADRs  No of reactions ADRs Proportion of Zaleplon ADRs  
Drug abuser (A1) + Drug diversion (A2) + Drug use disorder(A3) + 
Intentional product use issue (A4) + Intentional product misuse (A5) 
+Prescription drug used without prescription (A6) + Product use in 
unapproved indication (A7) + Product use issue (A8) + Substance 
abuser (A9) + Substance use disorder (A10) 
367 0.089 
Dependence (A11) 5 0.001 
Withdrawal syndrome (A12) + Drug withdrawal syndrome (A13) + 
Drug withdrawal headache (A14) + Drug withdrawal (A15) 
89 0.023 
Intentional overdose (A16) + Overdose (A17) 76 0.019 
Other Adverse Events (B) 3,733 0.868 
Total  4,270 1.000 
Zopiclone ADRs  No of reactions ADRs Proportion of Zopiclone ADRs 
Drug abuser (C1) + Drug diversion (C2) + Drug use disorder(C3) + 
Intentional product use issue (C4) + Intentional product misuse (C5) 
+ Prescription drug used without prescription (C6) + Product use in 
unapproved indication (C7) + Product use issue (C8) + Substance 
abuser (C9) + Substance use disorder (C10) 
2,507 0.043 
Dependence (C11) 138 0.002 
Withdrawal syndrome (C12) + Drug withdrawal syndrome (C13) + 
Drug withdrawal headache (C14) + Drug withdrawal (C15) 
718 0.013 
Intentional overdose (C16) + Overdose (C17) 5,920 0.096 
Other Adverse Events (D) 55,857 0.846 
Total  65,140 1.000 
Zolpidem ADRs  No of reactions ADRs Proportion of Zolpidem ADRs 
Drug abuser (E1) + Drug diversion (E2) + Drug use disorder (E2) + 
Intentional product use issue (E4) + Intentional product misuse (E5) 
+Prescription drug used without prescription (E6) + Product use in 
unapproved indication (E7) + Product use issue (E8) + Substance 
abuser (E9) + Substance use disorder (E10) 
9,744 0.050 
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Dependence (E11) 423 0.002 
Withdrawal syndrome (E12) + Drug withdrawal syndrome (E13) + 
Drug withdrawal headache (E14) + Drug withdrawal (E15) 
2,433 0.018 
Intentional overdose (E16) + Overdose (E17) 10,820 0.056 
Other Adverse Events (F) 182,895 0.874 
Total  206,315 1.000 
 
 
  
D
ow
nloaded from
 https://academ
ic.oup.com
/ijnp/advance-article-abstract/doi/10.1093/ijnp/pyz007/5306970 by :: user on 07 February 2019
Ac
ce
pte
d M
an
us
cri
pt
 
40 
 
Table 3: Z-drugs (zaleplon, zolpidem and zopiclone) PRR values  
 PRR Zolpidem vs Zaleplon 
(PRR- and PRR+) 
PRR Zopiclone vs Zaleplon 
(PRR- and PRR+) 
PRR Zolpidem vs Zopiclone 
(PRR- and PRR+) 
Misuse/abuse ADRs 0.57 (0.55-0.59) 0.48 (0.43-0.53) 1.16 (1.11-1.21) 
Dependence ADRs 2.00 (0.82-4.8) 2.00 (0.81-4.80) 1.00 
Withdrawal ADRs 0.79 (0.76-0.81) 0.56 (0.29-1.06) 1.38 (1.27-1.49) 
Overdose ADRs 2.90 (2.31-3.60) 5.00 (4.00-6.2) 0.58 (0.56-0.60) 
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